What is MS Phase 3 Study Fingolimod?
CATEGORY:
TYPES:Generic: Fingolimod Clinical Trial
NCT01201356 is a single arm, open-label study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis. Other study names are ID#CFTY720D2399 and 2010-020515-37.
Save up to 80% off your prescriptions!
How do members experience MS Phase 3 Study Fingolimod?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 1 | 0 | |
| Participate in clinical trial | 1 | 1 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Hair loss | 1 | |
| Headache on right side of head | 1 | |
| Itchy back | 1 | |
| Memory problems | 1 | |
| Nausea | 1 | |
| Nerve pain (neuralgia) | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 1 | |
| Mild | 0 | |
| None | 0 |
Learn more about our community’s experience with MS Phase 3 Study Fingolimod
What are people saying about MS Phase 3 Study Fingolimod?
2
2
members have reported taking MS Phase 3 Study Fingolimod
Join the conversation and connect with people who have taken MS Phase 3 Study Fingolimod
Last updated: